Slide 1: 2Q26 Earnings Presentation
2Q26 Earnings Presentation August 7, 2026
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 2Q26 Highlights
2Q26 Highlights 7.6% INCREASE IN PHARMACEUTICAL RETAIL SELL-OUT¹ +1.4 PERCENTAGE POINT ABOVE THE MARKET GROWTH IN THE CATEGORIES IN WHICH THE COMPANY OPERATES NET REVENUE: +8.5%² GROSS PROFIT: +11.5%² EBITDA FROM CONTINUING OPERATIONS: R$754.9 MILLION NET EARNINGS FROM CONTINUING OPERATIONS: +15.0%²
Slide 4: 2Q26 Highlights
2Q26 Highlights TREATMENT OF MENOPAUSAL VASOMOTOR SYMPTOMS • Partnership for the non-hormonal treatment of menopausal vasomotor symptoms, which affect up to 80% of the approximately 30 million Brazilian women living in the peri or post menopausal stage.¹ ENTRY INTO THE GLP-1 ANALOG MARKET WITH SEMAV
Slide 5: 2Q26 Results (R$ million)
2Q26 Results (R$ million) NET REVENUE R$ 2,336.7 +8.5%1 GROSS MARGIN 61.8%2 +1.7pp3 MARKETING EXPENSES R$ 410.9 +0.8pp3 SELLING EXPENSES R$ 272.3 +1.0pp3 GENERAL AND ADMINISTRATIVE EXPENSES R$ 97.4 +0.8pp3 EBITDA FROM CONTINUING OPERATIONS R$ 754.9 +4.1%1 NET EARNINGS FROM CONTINUING OPERATIONS R$ 4
Slide 6: 2Q26 Cash Flow (R$ million)
2Q26 Cash Flow (R$ million) 819 638 (76) (107) 2.1x 2,311 (1,343) (27) EBITDA 1,579 (5,903) (7,482) Gross Cash at the Cash Flow From PP&E Intangibles 2Q26 Free Cash Financing Cash IoC Gross Cash at the Gross Debt at the Net Debt at the end of 1Q26 Operations Flow Flow end of 2Q26 end of 2Q26 end of
Slide 7: Slide 7